All In Biotech

Drug Trial Radar · NCT04204057

Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

A Phase 2, Open Label Study to Assess the Efficacy and Safety of Tenalisib (RP6530), a Novel PI3K Dual δ/γ Inhibitor, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Last checked: Nov 19, 2026Latest source record: Aug 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

21

Actual

Start

Nov 28, 2019

Primary completion

Oct 2, 2020

Study completion Oct 2, 2020

Sponsor

Lead sponsor
Rhizen Pharmaceuticals SAIndustry
Sponsor type
Industry
First posted
Dec 18, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The trial is a Phase II, open label, Simon's two stage study design to evaluate the efficacy and safety of Tenalisib in patients with CLL who have relapsed or are refractory after at least one prior therapy.

Conditions

  • Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

  • TenalisibDrug

    Tenalisib 800 mg BID, Orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR)Time frame: 7 Months
  2. Duration of Response (DoR)Time frame: 7 Months

Locations

6 sites in 3 countries. Site status is shown where the registry gives one.

  • University Multiprofile Hospital for Active Treatment "Dr Georgi Stranski" Ltd.,

    Pleven, Bulgaria

  • University Multiprofile Hospital for Active Treatment "Sv Ivan Rilski" Ltd

    Sofia, Bulgaria

  • Ltd. M.Zodelava Hematology Centre

    Tbilisi, Georgia

  • Medivest - Institute of Hematology and Transfusiology

    Tbilisi, Georgia

  • Silesian Healthy Blood Clinic Grosicki, Grosicka Sp.J.

    Chorzów, Poland

  • Voivodship Multi-Specialist Center for Oncology and Traumatology M. Copernicus

    Lodz, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.